A PYMNTS Company

US: AbbVie hit with antitrust lawsuit over Humira “patent thicket”

By  |  March 20, 2019

AbbVie used a dense web of 100-plus patents to insulate its blockbuster drug Humira from US competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The lawsuit, filed on Monday, March 18, in Chicago federal court, accused AbbVie of using a so-called “patent thicket” to maintain a monopoly over the US$20-billion-a-year drug, which is used to treat arthritis and other diseases.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.